Literature DB >> 8700537

An abundance of p53 null mutations in ovarian carcinoma.

J S Skilling1, A Sood, T Niemann, D J Lager, R E Buller.   

Abstract

Ovarian cancers from 64 midwestern US women were screened for p53 dysfunction both by immunohistochemical staining (IHCS) and single strand conformation polymorphism (SSCP) analysis of the entire open reading frame (ORF). Forty SSCP abnormalities in 39 tumors included nine deletion, one insertion, two splice junction, two nonsense, one silent and 25 missense mutations were confirmed by direct genomic sequencing. Eight of the insertion/deletion defects may have occurred due to slippage during the course of DNA replication. This observation suggests that genomic instability may play an important role in ovarian carcinogenesis. Fifteen percent of the mutations encountered were located outside exons 5-9 and four of these were null. The sensitivity of IHCS was 96% for missense mutations but only 14% for null mutations. This contrasted with 100% sensitivity of the SSCP screening methodology. The 21% overall incidence of null mutations in the present study far exceeds the reported 6.8% incidence in the world literature (P=0.0003). Explanations for this difference include: (1) our complete analysis of the entire ORF of the p53 gene; (2) the tendency of others to rely upon IHCS to screen tumors prior to mutation analysis; and (3) environmental or endogenous genetic influences.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8700537

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

Review 1.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

2.  Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.

Authors:  Pang-ning Teng; Nicholas W Bateman; Kathleen M Darcy; Chad A Hamilton; George Larry Maxwell; Christopher J Bakkenist; Thomas P Conrads
Journal:  Gynecol Oncol       Date:  2015-01-02       Impact factor: 5.482

Review 3.  Microenvironment and pathogenesis of epithelial ovarian cancer.

Authors:  Antonio F Saad; Wei Hu; Anil K Sood
Journal:  Horm Cancer       Date:  2010-12       Impact factor: 3.869

4.  Genomic aberrations in borderline ovarian tumors.

Authors:  Francesca Micci; Lisbeth Haugom; Terje Ahlquist; Hege K Andersen; Vera M Abeler; Ben Davidson; Claes G Trope; Ragnhild A Lothe; Sverre Heim
Journal:  J Transl Med       Date:  2010-02-26       Impact factor: 5.531

5.  Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.

Authors:  R P Zweemer; P A Shaw; R M Verheijen; A Ryan; A Berchuck; B A Ponder; H Risch; J R McLaughlin; S A Narod; F H Menko; P Kenemans; I J Jacobs
Journal:  J Clin Pathol       Date:  1999-05       Impact factor: 3.411

6.  The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer.

Authors:  Dirk O Bauerschlag; Christian Schem; Marion T Weigel; Constantin Von Kaisenberg; Alexander Strauss; Thomas Bauknecht; Nicolai Maass; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

Review 7.  Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Authors:  Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin
Journal:  Mol Oncol       Date:  2009-02-21       Impact factor: 6.603

8.  Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors.

Authors:  E W Newcomb; M Sosnow; R I Demopoulos; A Zeleniuch-Jacquotte; J Sorich; J L Speyer
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

9.  Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.

Authors:  M Schuyer; M E van der Burg; S C Henzen-Logmans; J H Fieret; J G Klijn; M P Look; J A Foekens; G Stoter; E M Berns
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

10.  TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival.

Authors:  Y Wang; A Helland; R Holm; H Skomedal; V M Abeler; H E Danielsen; C G Tropé; A-L Børresen-Dale; G B Kristensen
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.